Press releases & news

 

2cureX continues to update its frequently asked Question page on www.2curex.com

2018-07-20

News

 

2cureX AB (“2cureX”) announced today that as part of its constructive and active dialogue with its stakeholders the 2cureX Q&A section on the website has been updated: https://www.2curex.com/investors/questions-and-answers/

 

 

 

Certified Adviser

Sedermera Fondkommission is the Certified Adviser of 2cureX.

 

For more information about 2cureX:

Ole Thastrup, CEO;

E-mail: ot@2cureX.com

Phone: +45 22 11 53 99;

URL: www.2curex.com

 

About 2cureX

2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient’s tumor. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.

 

IndiTreat® is currently being clinically validated in colorectal and ovarian cancer.

 

The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).

 

Contact information

Laboratory: 2cureX, Fruebjergvej 3, 2100 Copenhagen Ø, Denmark| Phone: +45 2211 5399| E-mail: info@2curex.com

Privacy Policy | Imprint